CDNA Long Call Strategy
CDNA (CareDx, Inc), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing.
CDNA (CareDx, Inc) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $4.09B, a trailing P/E of 31.55, a beta of 2.49 versus the broader market, a 52-week range of 15.15-90.87, average daily share volume of 1.3M, a public-listing history dating back to 2014, approximately 763 full-time employees. These structural characteristics shape how CDNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.49 indicates CDNA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on CDNA?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
CDNA snapshot
As of November 13, 2026, spot at $78.66, ATM IV 58.30%, IV rank 7.18%, expected move 16.71%. The long call on CDNA below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.
Why this long call structure on CDNA specifically: CDNA IV at 58.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a CDNA long call, with a market-implied 1-standard-deviation move of approximately 16.71% (roughly $13.15 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CDNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on CDNA should anchor to the underlying notional of $78.66 per share and to the trader's directional view on CDNA stock.
CDNA long call setup
The CDNA long call below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CDNA at $78.66 on that close, the first option leg uses a $80.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CDNA chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CDNA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $80.00 | $2.63 |
CDNA long call risk and reward
- Net Premium / Debit
- -$262.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$262.50
- Breakeven(s)
- $82.63
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CDNA long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CDNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$262.50 |
| $17.40 | -77.9% | -$262.50 |
| $34.79 | -55.8% | -$262.50 |
| $52.18 | -33.7% | -$262.50 |
| $69.57 | -11.6% | -$262.50 |
| $86.97 | +10.6% | +$434.03 |
| $104.36 | +32.7% | +$2,173.13 |
| $121.75 | +54.8% | +$3,912.24 |
| $139.14 | +76.9% | +$5,651.34 |
| $156.53 | +99.0% | +$7,390.45 |
When traders use long call on CDNA
Long calls on CDNA express a bullish thesis with defined risk; traders use them ahead of CDNA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CDNA thesis for this long call
The market-implied 1-standard-deviation range for CDNA extends from approximately $65.51 on the downside to $91.81 on the upside. A CDNA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CDNA IV rank near 7.18% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CDNA at 58.30%. As a Healthcare name, CDNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CDNA-specific events.
CDNA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CDNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CDNA alongside the broader basket even when CDNA-specific fundamentals are unchanged. Long-premium structures like a long call on CDNA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CDNA chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CDNA?
- A long call on CDNA is the long call strategy applied to CDNA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CDNA stock at $78.66 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed CDNA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CDNA long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CDNA long call priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 58.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$262.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CDNA long call?
- The breakeven for the CDNA long call priced on this page is roughly $82.63 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CDNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 16.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CDNA?
- Long calls on CDNA express a bullish thesis with defined risk; traders use them ahead of CDNA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CDNA implied volatility affect this long call?
- CDNA ATM IV is at 58.30% with IV rank near 7.18%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.